Discontinued — last reported Q4 '25
Natera, Inc. Contract Liabilities decreased by 0.4% to $17.00M in Q1 2026 compared to the prior quarter. Over 5 years (FY 2020 to FY 2025), Contract Liabilities shows a downward trend with a -5.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong future revenue visibility and customer demand, while a decrease may indicate faster fulfillment or slowing sales.
This represents the obligation to transfer goods or services to a customer for which the company has already received co...
Common in companies with long-term service contracts or subscription-based diagnostic models; peers with high recurring revenue often show higher balances.
contract_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.56M | $22.71M | $21.32M | $20.54M | $20.72M | $20.41M | $20.00M | $21.51M | $21.50M | $21.03M | $19.13M | $16.84M | $17.06M | $17.00M |
| QoQ Change | — | -3.6% | -6.1% | -3.6% | +0.9% | -1.5% | -2.0% | +7.5% | -0.0% | -2.2% | -9.1% | -12.0% | +1.3% | -0.4% |
| YoY Change | — | — | — | — | -12.1% | -10.1% | -6.2% | +4.7% | +3.8% | +3.1% | -4.4% | -12.0% | +1.3% | — |
| Segment | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Royalty | — | — | — | — | — | — | $1.40M | $500.00K |
| Oncology Assay Interpretation Services | $200.00K | $700.00K | $1.20M | $3.20M | $18.90M | $3.00M | — | — |
| Total | $21.50M | $21.03M | $19.13M | — | — | — | $16.84M | $17.06M |
Oncology Assay Interpretation Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.